Does Rallies show Form 4 insider transactions for AARD?

Yes. Rallies tracks AARD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AARD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AARD. It does not provide personalized investment advice.

AARD (Aardvark Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Aardvark Therapeutics, Inc. Common Stock (AARD) is a publicly traded Healthcare sector company. As of May 21, 2026, AARD trades at $4.40 with a market cap of $95.12M and a P/E ratio of -1.33. AARD moved -1.49% today. Year to date, AARD is -67.70%; over the trailing twelve months it is -61.00%. Its 52-week range spans $3.35 to $19.58. Analyst consensus is buy with an average price target of $15.14. Rallies surfaces AARD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AARD stock inside the company?

Recent AARD insider activity includes Sun Nelson bought 3.00K, Lee Tien-Li bought 7.00K, Lee Tien-Li bought 6.50K, Lee Tien-Li bought 3.50K, and Lee Tien-Li bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AARD Key Metrics

Key financial metrics for AARD
Metric	Value
Price	$4.40
Market Cap	$95.12M
P/E Ratio	-1.33
EPS	$-3.21
Dividend Yield	0.00%
52-Week High	$19.58
52-Week Low	$3.35
Volume	2
Avg Volume	0
Revenue (TTM)	$-1.18M
Net Income	$-69.87M
Gross Margin	0.00%

Recent AARD Insider Trades

Sun Nelson bought 3.00K (~$43.20K) on Dec 11, 2025.
Lee Tien-Li bought 7.00K (~$101.39K) on Dec 11, 2025.
Lee Tien-Li bought 6.50K (~$61.82K) on Sep 15, 2025.
Lee Tien-Li bought 3.50K (~$34.80K) on Sep 15, 2025.
Lee Tien-Li bought 5.00K (~$42.52K) on Sep 12, 2025.

Latest AARD News

Aardvark to Unblind ARD-101 Data After FDA’s Full Clinical Hold — May 14, 2026
Aardvark Pauses ARD-101 Phase 3 HERO and ARD-201 Trials After Cardiac Findings — May 7, 2026
Aardvark Therapeutics Pauses Phase 3 Trial After Cardiac Signals, Shares Drop 61% — Mar 4, 2026
Aardvark Expands Phase 3 HERO Trial to Ages 7+, Seeks FDA Approval — Feb 10, 2026

AARD Analyst Consensus

10 analysts cover AARD: 0 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.14.

Common questions about AARD

Who is trading AARD stock inside the company?: Recent AARD insider activity includes Sun Nelson bought 3.00K, Lee Tien-Li bought 7.00K, Lee Tien-Li bought 6.50K, Lee Tien-Li bought 3.50K, and Lee Tien-Li bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AARD?: Yes. Rallies tracks AARD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AARD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AARD. It does not provide personalized investment advice.